Raising the Efficacy Bar in Hidradenitis Suppurativa: Translating Phase 1 Data for Dual OX40L/TNFα Inhibition into the Next Generation of Disease Control
- Evaluating the clinical rationale for simultaneous OX40L and TNFα inhibition to address multiple inflammatory pathways driving HS pathogenesis and disease heterogeneity
- Reviewing Phase 1 safety, tolerability and pharmacokinetic findings supporting further development and potential once-monthly dosing in patients with HS
- Exploring how bispecific antibody approaches could improve upon TNFα monotherapy to deliver more durable responses and raise the standard of care in moderate-to-severe HS